Carbon monoxide (CO) exerts protective effects on hepatic ischemia/reperfusion injury (IRI), but the underlying molecular mechanisms are not fully understood. High-mobility group box 1 (HMGB1) is an important mediator of injury and inflammation in hepatic IRI. Here, we investigated whether CO could attenuate hepatic IRI via inhibition of HMGB1 release, particularly through sirtuin 1 (SIRT1). CO was released by treatment with carbon monoxide-releasing molecule (CORM)-2. CORM-2-delivered CO ameliorated hepatic IRI, as indicated by lower serum aminotransferase levels, lower hepatic inflammatory responses, and less severe ischemia/reperfusion-associated histopathologic changes. Treatment with CORM-2 significantly inhibited IRI-induced HMGB1 translocation and release. SIRT1 expression was increased by CORM-2 pretreatment. When CORM-2-induced SIRT1 expression was inhibited using EX527, HMGB1 translocation and release were increased and hepatic IRI was worsened, whereas SIRT1 activation by resveratrol reversed this trend. In vitro, CORM-2 reduced hypoxia/reoxygenation-induced HMGB1 translocation and release, these inhibitions were blocked by SIRT1 inhibition using EX527 or SIRT1 small interfering RNA both in alpha mouse liver 12 cells and RAW264.7 macrophages. Moreover, SIRT1 directly interacted with and deacetylated HMGB1. IRI increased HMGB1 acetylation, which was abolished by CORM-2 treatment via SIRT1. In conclusion, these results suggest that CO may increase SIRT1 expression, which may decrease HMGB1 acetylation and subsequently reduce its translocation and release, thereby protecting against hepatic IRI.
box 1 (HMGB1), from immune cells and injured liver cells may critically contribute to the propagation of the inflammatory response and further liver injury after reperfusion. (2) HMGB1 is an evolutionarily conserved nuclear protein that can bend DNA and promote the assembly of nucleoprotein complexes, thereby facilitating gene transcription and nucleosome stabilization. (3) In addition to its nuclear role, HMGB1 also behaves as a proinflammatory cytokine when passively released by damaged cells or actively secreted by immune cells. (4) (5) (6) HMGB1 is released following hepatic IRI, (7) (8) (9) and treatment with a neutralizing antibody to HMGB1 significantly decreases liver injury, (10) suggesting that HMGB1 may act as a critical mediator of inflammation and injury in the setting of hepatic IRI. Therefore, inhibiting HMGB1 translocation and release should attenuate liver injury and might represent a novel therapeutic strategy in hepatic IRI.
Posttranslational modifications, including acetylation, (11) phosphorylation, (12) methylation, (13) and oxidation, (14, 15) have all been shown to influence the HMGB1 subcellular location in response to various stimuli. Hyperacetylation on 2 major clusters of lysine residues within 2 nuclear localization sequence sites of HMGB1 has been implicated in its nuclear-tocytoplasmic translocation in macrophages. (11) Recent studies have demonstrated that HMGB1 is acetylated and released from hepatocytes and neuronal cells during IRI, which is associated with the decreased activity of histone deacetylases (HDACs) isoforms HDAC1 and HDAC4 in hepatocytes (9) and HDAC4 and HDAC5 (16) in neuronal cells. Sirtuin 1 (SIRT1), an nicotinamide adenine dinucleotide (NAD) 1 -dependent class III protein deacetylase, is implicated in diverse cellular processes, such as energy metabolism, stress resistance, and inflammation. (17) (18) (19) Notably, recent reports suggest that SIRT1 interacts with HMGB1 and regulates HMGB1 translocation and release via deacetylation. (20) (21) (22) Carbon monoxide (CO), a reaction product of heme oxygenase-1 activity, has been shown to exhibit potent antioxidant, anti-inflammatory, and antiapoptotic effects and thereby can ameliorate hepatic IRI. (23) (24) (25) (26) Therapeutic up-regulation of CO tissue levels can be achieved by exogenous application of CO, including direct inhalation of CO gas or administration of carbon monoxide-releasing molecules (CORMs). Although much work has indicated the protective effects of CO on hepatic IRI, the underlying molecular mechanisms are not fully understood.
Thus far, whether the protective effects of CO on hepatic IRI show any correlation with HMGB1 release remains unclear. Because CO may increase SIRT1 activity, (27) it is possible that CO may regulate HMGB1 release via SIRT1 deacetylation. Therefore, the aim of this study was to investigate whether CO could possess anti-inflammatory abilities to protect from or reduce hepatic IRI via SIRT1-mediated HMGB1 deacetylation.
Materials and Methods

EXPERIMENTAL DESIGN
To investigate whether CO could protect against hepatic IRI via inhibition of HMGB1 release, rats were pretreated with tricarbonyldichlororuthenium (II) dimer ([Ru(CO) 3 Cl 2 ] 2 , CORM-2, 8 mg/kg, intravenous (i.v.) Sigma-Aldrich, St. Louis, MO) to release CO 1 hour prior to warm ischemia. Control rats were injected with inactive carbon monoxidereleasing molecule (iCORM)-2 (8 mg/kg). The rats were killed 6 hours after reperfusion. Liver injury and HMGB1 translocation and release were analyzed. In vitro, alpha mouse liver 12 (AML12) cells (American Type Culture Collection, Manassas, VA) transfected with HMGB1-green fluorescent protein (GFP) plasmid (OriGene, Rockville, MD) for 24 hours were pretreated with either CORM-2 (50 lM) or iCORM-2 (50 lM) for 2 hours and then subjected to hypoxia/reoxygenation (H/R) injury. RAW264.7 macrophages (American Type Culture Collection) were pretreated with either CORM-2 (50 lM) or iCORM-2 (50 lM) for 2 hours and then subjected to H/R injury. HMGB1 translocation and release were analyzed. CORM-2 was prepared in dimethylsulfoxide (DMSO) and further diluted in saline to a final concentration of 10% DMSO for in vivo injection. iCORM-2 was prepared by incubating CORM-2 dissolved in DMSO for 24 hours at 378C in a 5% CO 2 humidified atmosphere to liberate CO. (28) To determine whether CORM-2-associated reductions in HMGB1 release were related to the lower hepatic inflammatory responses after reperfusion, we used the supernatants from hypoxic AML12 hepatocytes to stimulate RAW264.7 macrophages. Supernatants from hypoxic AML12 hepatocytes were harvested after a 20-hour hypoxic period. HMGB1 was extracted from hypoxic media by immunoprecipitation and used to stimulate RAW264.7 macrophages. Tumor necrosis factor a (TNF-a), interleukin (IL) 6, and IL1ß messenger RNA (mRNA) levels in macrophages were analyzed.
To investigate whether CO-associated reductions in HMGB1 release were regulated by SIRT1-mediated deacetylation, EX527 (5 mg/kg, i.v., Selleck Chemicals, Houston, TX) was administered to rats 30 minutes prior to CORM-2 treatment to inhibit CO-induced SIRT1 activity. Resveratrol (10 mg/kg, intraperitoneal (i.p.), Sigma Aldrich) was administered to rats daily for 1 week followed by an i.p. injection of the same dose 30 minutes prior to warm ischemia. (22) Liver injury, acetylated HMGB1, and HMGB1 translocation and release were analyzed. In vitro, CO-induced SIRT1 activity was inhibited by EX527 (10 lM, 1 hour) or SIRT1 small interfering RNA (siRNA; 50 nM, 48 hours, Life Technologies, Carlsbad, CA), and SIRT1 activity was increased by resveratrol (10 lM, 2 hours) prior to H/R injury. HMGB1 translocation and release were analyzed. EX527 or resveratrol was dissolved in DMSO.
ANIMALS
Male inbred Sprague-Dawley rats weighing 250-300 g were purchased from the Hubei Provincial Center for Disease Control and Prevention (Wuhan, China). All animals were housed under standard animal care conditions and had free access to water and food. 
PARTIAL HEPATIC WARM ISCHEMIA/REPERFUSION
A partial hepatic warm ischemia/reperfusion (I/R) model was generated as previously described. (7) A microvascular clamp was used to interrupt the arterial and portal venous blood supply to the left lateral and median liver lobes to produce 70% hepatic ischemia. After 60 minutes, the clamp was removed, followed by 6 hours of reperfusion.
LIVER DAMAGE ASSESSMENT
Serum alanine transaminase (ALT) and aspartate aminotransferase (AST) were measured using an automated chemical analyzer (Hitachi Co, Tokyo, Japan).
HISTOPATHOLOGY
The isolated left lateral segment of the liver lobes was fixed in 4.5% buffered formalin. Paraffin-embedded liver sections were cut and stained with hematoxylineosin for pathological evaluation. Histological necrosis evaluation was performed according to a standardized semiquantitative scoring system. (29) IMMUNOHISTOCHEMISTRY Immunohistochemistry was performed as described previously. (7) Briefly, after deparaffinization, rehydration, and antigen retrieval, the sections were incubated with myeloperoxidase (MPO) antibody (1:50; Abcam, Cambridge, UK), CD68 antibody (1:100; Abcam), and HMGB1 antibody (1:500; Abcam) for 1 hour at room temperature. After washing, the sections were incubated with goat anti-rabbit secondary antibody and visualized with diaminobenzidine. The numbers of both CD68-positive macrophages and MPOpositive neutrophils were counted in 5 fields/section under a microscope (3400), and the number of cells/ field was shown. (30) The percentage of hepatocytes with cytoplasmic HMGB1 staining out of the total number of hepatocytes was calculated as described previously. 
IMMUNOPRECIPITATION ANALYSIS
Immunoprecipitation experiments were performed using a commercial Crosslink immunoprecipitation kit (Thermo Pierce). Briefly, HMGB1 antibody (10 lg, Abcam), SIRT1 antibody (10 lg, Cell Signaling Technology, Beverly, MA), or acetyl-lysine antibody (10 lg, Abcam) was covalently crosslinked onto protein A/G resin. Normal rabbit immunoglobulin G (IgG; Sigma-Aldrich) was used as a negative control. Samples were first precleared using the control agarose resin. Precleared lysates were then incubated with protein A/G beads which were coupled with anti-HMGB1, anti-SIRT1, or anti-acetyl-lysine antibodies at 48C overnight. After washing with phosphatebuffered saline, the proteins were eluted from the beads by using antigen elution buffer and were then subjected to Western blotting analysis.
GEL ELECTROPHORESIS AND WESTERN BLOTTING
Western blotting was performed as described previously. (7) Membranes were incubated overnight with primary rabbit anti-HMGB1 antibody (1:1000, Abcam), rabbit anti-SIRT1 antibody (1:1000, Cell Signaling Technology), rabbit anti-acetyl-lysine antibody (1:1000, Abcam), and anti-ß-actin (1:10000, Abcam). Detection was performed using enhanced chemiluminescence (Thermo Pierce), and Western blots were visualized on the Kodak Image Station (Carestream Health Inc, Rochester, NY).
ENZYME-LINKED IMMUNOSORBENT ASSAY
The levels of HMGB1 in serum and cultured medium were measured according to the instructions of the manufacturer (Shino-Test, Kanagawa, Japan).
SIRT1 DEACETYLATION OF HMGB1
SIRT1 deacetylation of HMGB1 was performed as described previously. (22) Briefly, acetylated HMGB1 samples (obtained from liver lysates after 60 minutes of ischemia and 6 hours of reperfusion) were incubated in a Sirtuin assay buffer (50 mM Tris-HCl [pH 8.0], 137 mM NaCl, 2.7 mM KCl, 1 mg/mL BSA) with recombinant SIRT1 enzyme (rSIRT1) and SIRT1 cofactors (500 lM NAD 1 and 1 mM MgCl 2 ; Enzo Life Sciences, Farmingdale, NY). After 1 hour of incubation, acetylated HMGB1 was analyzed.
CELL CULTURE AND H/R MODEL IN VITRO
The differentiated nontransformed mouse hepatocyte cell line AML12 cells were cultured in Dulbecco's modified Eagle's medium (DMEM)/F12 medium (Gibco, Gaithersburg, MD) supplemented with 10% fetal bovine serum (Gibco), 13 Insulin-TransferrinSelenium-G Supplement (Gibco), 40 ng/mL dexamethasone (Sigma-Aldrich), 100 IU/mL penicillin, and 100 lg/mL streptomycin at 378C with 5% CO 2 . RAW264.7 macrophages were cultured in DMEM (Gibco) supplemented with 10% fetal bovine serum, 100 IU/mL penicillin, and 100 lg/mL streptomycin. To establish an H/R model in vitro, AML12 cells or RAW264.7 macrophages were placed into serum-free DMEM/F12 or DMEM in a hypoxia chamber (Thermo Scientific) flushed with 1% O 2 , 5% CO 2 , and 94% N 2 for 20 hours followed by reoxygenation for 2 hours.
HMGB1-GFP PLASMID TRANSFECTION
AML12 cells were transfected with HMGB1-GFP plasmid using Lipofectamine 3000 reagent (Invitrogen, Carlsbad, CA) following the manufacturer's instructions. After transfection for 24 hours, the AML12 hepatocytes were subjected to H/R injury in the presence or absence of CORM-2 (50 lM), EX527 (10 lM), and resveratrol (10 lM). After treatment, the cells were fixed with 4% paraformaldehyde. Micrographs were obtained with an inverted Olympus FV1000 laser scanning confocal microscope (Olympus, Tokyo, Japan). Cytoplasmic HMGB1 immunofluorescence intensity was measured using National Institutes of Health's ImageJ software.
siRNA TRANSFECTION SIRT1 siRNA transfection was conducted using Lipofectamine RNAiMAX reagent (Invitrogen) following the manufacturer's instructions. A scrambled siRNA was transfected as the negative control. After transfection for 48 hours, the cells were treated with different conditions for further analysis.
QUANTITATIVE POLYMERASE CHAIN REACTION
Real-time polymerase chain reaction (PCR) for TNFa, IL6, and IL1ß was performed as described previously. (31) Total RNA was extracted by TRIzol Reagent (Invitrogen) according to the manufacturer's instructions. Briefly, 1 lg of total RNA was used for reverse transcription to synthesize complementary DNA (cDNA) using a First-Strand cDNA synthesis kit (Invitrogen). The PCR reaction mixture was prepared using an SYBR Green master mix (Toyobo, Osaka, Japan) with primers as described previously, (30, 31) and quantitative PCR was performed using a Roche Light cycle system (Roche, Rotkreuz, Switzerland). Relative quantification of target mRNA expression was calculated and further normalized to ß-actin mRNA.
STATISTICAL ANALYSIS
The data are expressed as the mean 6 standard deviation (SD). Differences among groups were evaluated for significance using a 1-way analysis of variance combined with Bonferroni's post hoc test. The SigmaStat software, version 3.5 (Systat-Software, Erkrath, Germany) was used for these analyses. A P value below 0.05 was considered to indicate statistical significance.
Results
CORM-2 PRETREATMENT PROTECTS AGAINST HEPATIC IRI
We previously demonstrated that CORM-2 pretreatment exerted protective effects on hepatic IRI in mice. (32) To determine whether CORM-2 could attenuate hepatic IRI in rats, the rats were treated with CORM-2 (8 mg/kg, i.v.) or iCORM-2 (8 mg/kg i.v.) 1 hour prior to warm ischemia. As shown in Fig. 1A , the serum levels of ALT and AST in rats subjected to hepatic IRI were significantly decreased in animals pretreated with CORM-2. The liver histology confirmed that treatment with CORM-2 resulted in a significant reduction of liver injury. Severe hepatocellular necrosis was present in the liver tissue from the iCORM-2 1 I/R group, whereas minimal damage was noted in samples from the CORM-2 1 I/R group (Fig. 1B) .
CORM-2-MEDIATED PROTECTION CORRELATES WITH MITIGATION OF THE INFLAMMATORY RESPONSE
The inflammatory response is a critical factor in IRI. (1) As shown in Fig. 1B , the number of both MPOpositive neutrophils and CD68-positive macrophages were increased in the iCORM-2 1 I/R group at 6 hours after reperfusion. The increased numbers of both CD68-positive macrophages and MPO-positive neutrophils following IRI were blocked by CORM-2 pretreatment (Fig. 1B) . The mRNA expression of several inflammatory mediators including TNF-a, IL6, and IL1ß mRNA was measured by quantitative PCR. In agreement, compared with sham-operated animals, hepatic TNF-a, IL6, and IL1ß mRNA expression levels were significantly increased in both iCORM-2-treated rats and CORM-2-injected rats. However, animals pretreated with CORM-2 exhibited minimal increases in hepatic TNF-a, IL6, and IL1ß mRNA compared with iCORM-2-treated rats (Fig. 1C) .
CORM-2 PROTECTS AGAINST HEPATIC I/R BY DECREASING HMGB1 TRANSLOCATION AND RELEASE
Hepatic IRI results in HMGB1 translocation and release, and HMGB1 is a key mediator of injury and inflammation following reperfusion. (7, 10) To determine whether CORM-2 pretreatment could prevent the nuclear-cytoplasmic trafficking of HMGB1 in ischemic liver tissues, immunohistochemical staining was performed to detect changes in the location of HMGB1. Cytoplasmic HMGB1 staining in hepatocytes was substantially increased after reperfusion. In contrast, CORM-2 pretreatment largely prevented this increase of cytoplasmic HMGB1 staining ( Fig. 2A) . Western blot analysis of hepatic cytoplasmic proteins further confirmed the HMGB1 translocation following ischemia. I/R increased cytoplasmic HMGB1 expression when compared with sham-operated rats. Notably, the CORM-2 pretreated rats exhibited minimal increase in cytoplasmic HMGB1 protein compared with iCORM-2-injected rats (Fig. 2B,C) . Furthermore, the serum HMGB1 levels were significantly increased in response to IRI. In contrast, the CORM-2-treated rats showed lower serum HMGB1 levels when compared with iCORM-2-injected rats (Fig. 2D) .
To confirm the in vivo inhibitory effects of CORM-2 on HMGB1 translocation and release during hepatic I/R, AML12 hepatocytes were exposed to H/R injury in the presence or absence of CORM-2. HMGB1 was predominantly located inside the nucleus in the cells cultured under normal conditions. After H/R injury, a significant increase in cytoplasmic HMGB1 was observed in iCORM-2-treated AML12 hepatocytes. In contrast, CORM-2 prevented the H/R-induced shuttling of HMGB1 from nucleus to cytoplasm. Furthermore, the levels of HMGB1 in the culture medium were increased after H/R, and CORM-2 significantly blunted the release of HMGB1 (Fig. 2E-G) . Consistent with these observations, CORM-2 also prevented the H/Rinduced HMGB1 translocation and release in RAW264.7 macrophages (Fig. 2H-J) .
To determine whether decreased HMGB1 release contributed to the lower hepatic inflammatory responses after reperfusion in CORM-2 pretreated rats, RAW264.7 macrophages were cultured overnight with hypoxic media either from CORM-2-or iCORM-2-treated AML12 hepatocytes. As shown in Fig. 3A , TNF-a, IL6, and IL1ß mRNA levels were significantly decreased in RAW264.7 macrophages after stimulation with hypoxic media from CORM-2-treated hepatocytes compared with hypoxic media from iCORM-2-treated hepatocytes. Furthermore, HMGB1 extracted from hypoxic media significantly increased TNF-a, IL6, and IL1ß mRNA levels in RAW264.7 macrophages (Fig. 3C ).
CORM-2-INDUCED PROTECTION IS MEDIATED BY SIRT1
Western blotting analysis showed an increase in SIRT1 protein expression in the liver from rats subjected to hepatic I/R compared with the sham group. Furthermore, the expression of SIRT1 was significantly increased by CORM-2 pretreatment following reperfusion (Fig. 4A,B) . To evaluate the potential role of SIRT1 in CORM-2-mediated liver protection, an SIRT1 inhibitor (EX527) was administered to rats prior to ischemia. The serum levels of ALT and AST were significantly increased in animals pretreated with EX527 (Fig. 4C) . To further determine if the protective effect of CORM-2 in hepatic IRI was associated with SIRT1 induction, rats were treated with the pharmacological SIRT1 inducer resveratrol prior to warm ischemia. Resveratrol treatment decreased the elevation of ALT and AST levels in response to I/R insult (Fig. 4D ).
CORM-2 INHIBITS HMGB1 CYTOPLASMIC TRANSLOCATION AND RELEASE THROUGH UP-REGULATION OF SIRT1
To determine whether CORM-2-associated reductions in HMGB1 translocation and release were regulated by SIRT1, the rats were pretreated with an SIRT1 inhibitor (EX527) prior to ischemia. As shown in Fig. 5 , EX527 treatment significantly prevented CORM-2-associated reductions in HMGB1 translocation and release in response to IRI (Fig. 5A-C,G) . In contrast, treatment with the SIRT1 inducer resveratrol prior to warm ischemia resulted in significant decreases in HMGB1 translocation and release following reperfusion when compared with the vehicle group (Fig. 5D-F,H) .
To confirm the role of SIRT1 in HMGB1 translocation and release during hepatic I/R, AML12 hepatocytes were treated with EX527 or SIRT1 siRNA and exposed to H/R injury. In control AML12 hepatocytes, HMGB1 was mainly localized to the nucleus. EX527 pretreatment promoted HMGB1 translocation into the cytoplasm and release. Furthermore, CORM-2-associated reductions in HMGB1 translocation and release were blocked by EX527 treatment after H/R injury ( Fig. 6A-C) . Similar to the effect of EX527, knockdown of SIRT1 using SIRT1 siRNA also prevented CORM-2-associated reductions in HMGB1 translocation and release (Fig. 6D-F) . In contrast, resveratrol prevented the H/R-induced translocation and release of HMGB1 (Fig. 6I-K) . Consistent with these observations, the inhibitory effect of CORM-2 on HMGB1 translocation and release was associated with SIRT1 in RAW264.7 macrophages (Fig. 7) . Taken together, our findings indicated that CORM-2 may inhibit HMGB1 cytoplasmic translocation and release through the up-regulation of SIRT1.
SIRT1 INTERACTS WITH AND DEACETYLATES HMGB1
To determine whether SIRT1 could interact with HMGB1 by deacetylating HMGB1, the interaction between HMGB1 and SIRT1 was examined by coimmunoprecipitation. Lysates of liver tissues were immunoprecipitated with an anti-HMGB1 antibody and followed by immunoblotting with an anti-SIRT1 antibody. As shown in Fig. 8A , the immunoprecipitation of HMGB1 from lysates of liver tissues resulted in the coprecipitation of SIRT1. The same result was obtained by using an anti-SIRT1 antibody for immunoprecipitation and an anti-HMGB1 antibody for immunoblotting of the precipitate, indicating a positive interaction between these 2 proteins.
To determine whether the process of HMGB1 translocation and release was regulated by SIRT1-mediated deacetylation, rats were pretreated with EX527 and the levels of acetylated HMGB1 were observed. The levels of acetylated HMGB1 were significantly increased following I/R insult. CORM-2 treatment reduced the levels of acetylated HMGB1 (Fig. 8B,C) . EX527 treatment prevented CORM-2-associated reduction in acetylated HMGB1 in response to IRI (Fig. 8D,E) . To further determine the possibility of SIRT1 targeting HMGB1 for deacetylation, acetylated HMGB1 was incubated with recombinant SIRT1 and cofactors NAD 1 and Mg 21 for 1 hour. As shown in Fig. 8F ,G, the acetylated HMGB1 levels were decreased after coincubation with recombinant SIRT1. Importantly, HMGB1 remained acetylated when we omitted the required SIRT1 cofactor NAD 1 or inactivated recombinant SIRT1. These findings suggest that HMGB1 may represent a substrate for SIRT1 deacetylation.
Discussion
CO has been shown to exert protective actions against hepatic IRI, but its regulatory mechanisms are limited. Here, we documented that CO liberated from CORM-2 potently attenuated hepatic IRI in rats.
Furthermore, the protective mechanism of CO on hepatic IRI was associated with increased SIRT1 expression, which was accompanied by decreased HMGB1 translocation and release, resulting in reduced inflammatory response and injury after reperfusion.
It has been reported that CO can provide significant protection in hepatic IRI. Exogenously provided CO ameliorated cold hepatic IRI in an ex vivo isolated liver perfusion model. (23) Likewise, in a rodent liver transplantation-induced IRI model, Ikeda et al. (24) showed that in vivo treatment of recipients with ) and sacrificed at 6 hours after reperfusion. Serum ALT and AST levels were quantified. (D) Rats were pretreated with resveratrol (10 mg/kg, i.p.) prior to ischemia and sacrificed at 6 hours after reperfusion. Serum ALT and AST levels were quantified. The data are shown as the mean 6 SD (n 5 6 per group). inhaled CO and ex vivo treatment of liver grafts with CO in a preservation solution ameliorated hepatic injury and improved graft survival. Furthermore, several studies demonstrated that exogenously delivered CO also conferred protective effects on warm hepatic IRI. (26, 27) Recent findings from our laboratory also demonstrated that CORM-2-delivered CO ameliorated hepatic injury after reperfusion in mice. 
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Consistent with these observations, in the current study, we demonstrated that CO liberated from CORM-2 had an extremely potent protective effect on hepatic IRI, as evidenced by lower serum aminotransferase levels, lower inflammatory responses, and less severe I/R-associated histopathologic changes. These findings suggest that CO has highly favorable characteristics for the reduction of hepatic IRI. The mechanisms of the protective actions of CO are being extensively investigated. It has been proposed that the protective effects of CO might be mediated by binding to heme-containing enzymes (such as cytochrome c oxidase, cytochrome P450, and guanylyl cyclase) and modulating the P38-mitogen-activated protein kinase (MAPK) pathway. (23, (33) (34) (35) CO inhibits intercellular cell adhesion molecule expression in liver grafts during IRI. (24) CO is shown to exert an antiapoptotic effect by down-regulating proapoptotic signals such as B cell lymphoma-2-associated X and caspase 3 and by up-regulating antiapoptotic signals of the B cell lymphoma-2 family. (25, 26) Moreover, CO confers anti-inflammatory protection in hepatic IRI by inhibiting the inflammatory response of donor Kupffer cells upon transplantation, (36) activating the antiinflammatory MAPK pathway, (37) maintaining glycogen synthase kinase 3b phosphorylation, (38) and modulating the microRNA-34a/SIRT1 pathway. (27) Recent evidence in animal models indicates that HGMB1 is an early mediator of injury and inflammation in hepatic IRI. (10) HMGB1 is mainly located in the nucleus and participates in chromatin architectural remodeling and transcriptional regulation. When HMGB1 is released in response to various stimuli, it interacts with toll-like receptors (TLRs) and receptors for advanced glycation end-products and generates an inflammatory response. (7, 10) As a result, treatment with a neutralizing antibody to HMGB1 significantly decreases I/R-induced proinflammatory cytokine expression, resulting in inhibition of hepatic inflammation and injury after reperfusion. (10) Thus far, it is not yet clear whether CO could reduce hepatic IRI by inhibition of HMGB1 release. Recently, Tsoyi et al. (39) demonstrated that CORM-2 inhibited HMGB1 release in TLR-activated macrophages in vitro and reduced plasma HMGB1 levels in septic mice in vivo. Sahara et al. (40) documented that CO inhalation dramatically decreased HMGB1 levels and ameliorated lung IRI. Ogaki et al. (41) showed that CO bound to red blood cells suppressed hepatic HMGB1 mRNA expression after hemorrhagic shock. These observations were confirmed by Ruan et al., (28) who showed that CORM-2 prevented ischemia-induced HMGB1 translocation and release and protected against lethal renal IRI. In agreement with these findings, our results showed that CORM-2 treatment led to lower hepatic HMGB1 translocation and serum levels. Furthermore, HMGB1 extracted from hypoxic media significantly increased TNF-a, IL6, and IL1ß mRNA levels in RAW264.7 macrophages. These findings suggested that the mechanism of protective action of CO appears to involve its ability to reduce I/R-induced-HMGB1 release.
How CO inhibits HMGB1 translocation and release remains unclear. Recent studies have demonstrated that HMGB1 translocation and release is regulated by several posttranslational modifications, including acetylation, (11) phosphorylation, (12) methylation, (13) and oxidation. (14, 15) HMGB1 can be acetylated by histone acetyltransferases, including p300/CREB binding protein-associated factor, CREB binding protein, and p300. (11) Posttranslational modification by acetylation appears to be critical for the active secretion of HMGB1 by stimulated immune cells such as macrophages. (11) It also has been reported that serum HMGB1 released following hepatic I/R in vivo is acetylated and that hepatocytes exposed to oxidative stress in vitro also release acetylated HMGB1. (9) HDACs, a family of enzymes, play important roles in regulating the acetylation status of nonhistone proteins. (42) It has been reported that decreased nuclear HDAC1 and HDAC4 activity in hepatocytes following hepatic I/R is a mechanism that promotes the hyperacetylation and subsequent release of HMGB1, (9) and the loss of HDAC4 and HDAC5 activity is also responsible for HMGB1 release in neuronal cells during cerebral IRI. (16) Recent findings also suggest that the activation of histone acetyltransferases during I/R also contributes to HMGB1 acetylation. (43) Additionally, SIRT1 can directly bind to HMGB1 and deacetylate HMGB1, thereby determining its translocation from the nucleus to the cytoplasm. (20) (21) (22) SIRT1 deacetylates HMGB1 at lysine residues 55, 88, 90, and 177, which impacts HMGB1 translocation and release and its proinflammatory activity. (22) Furthermore, CO increases SIRT1 activity via down-regulation of the microRNA-34a signaling pathway. (27) Consistent with these observations, we demonstrated that SIRT1 can interact with and deacetylate HMGB1. CORM-2 treatment induced a significant increase in SIRT1 expression, whereas it decreased the acetylated HMGB1 in response to IRI. Inhibition of SIRT1 activity using EX527 significantly blocked the CORM-2-associated reductions in HMGB1 translocation and release and attenuated the CORM-2-conferred protection. In contrast, induction of SIRT1 activity using resveratrol significantly reduced HMGB1 translocation and release and protected against hepatic IRI. These results suggested that SIRT1 expression can be modulated by CORM-2 and that interfering or augmenting the activity of SIRT1 can independently alter HMGB1 translocation and release. Therefore, SIRT1 appears to be a mediator of HMGB1 translocation and release in CO modulation of hepatic IRI.
In summary, we documented that CO delivered through CORM-2 administration could ameliorate hepatic IRI in rats, and the protective mechanism appeared to involve its ability to inhibit HMGB1 translocation and release by SIRT1 deacetylation.
